What are tumor markers (tumor indices)? Does a high value mean cancer? Common markers and correct interpretation
Tumor markers (tumor indices) are measurable substances in the blood that may be produced by cancer cells, by the body in response to cancer, or by benign (non-cancerous) conditions. A high value does not equal cancer—inflammation, smoking, pregnancy, liver/kidney issues, etc., can also cause elevations; a normal value cannot completely rule out cancer. According to the U.S. National Cancer Institute (NCI), most tumor markers are not recommended as standalone screening tools for asymptomatic individuals; they are mainly used for treatment monitoring and follow-up in diagnosed patients. Below is a summary of common markers, their significance, and correct interpretation—neutral information, not medical diagnosis or advice. Please discuss results with your physician.
What are tumor markers? Can they be used to screen for cancer?
Tumor markers are substances measurable in blood that may be produced by cancer cells, the body's response to cancer, or benign conditions. According to the U.S. National Cancer Institute (NCI), most circulating tumor markers are 'ineffective' (insufficient sensitivity and specificity) for screening asymptomatic individuals and are not recommended as general screening tools:
- Primary legitimate use: monitoring treatment response and recurrence in patients with confirmed cancer
- A few defined high-risk groups have a monitoring role (e.g., liver cirrhosis patients monitored with AFP + abdominal ultrasound for hepatocellular carcinoma)
- Diagnosis still requires integration of clinical, imaging, and pathological (biopsy) findings; a single value cannot diagnose cancer
Does an elevated level mean cancer?
No. According to the NCI, an elevated tumor marker does not mean cancer—many benign conditions can cause elevation; conversely, a normal value does not rule out cancer (false negative). Interpreting a single number can be misleading:
- Elevation may be due to benign causes such as inflammation, infection, smoking, pregnancy, or liver/kidney dysfunction
- A normal value does not guarantee absence of cancer (some cancers do not elevate corresponding markers)
- An isolated abnormal value requires clinical context interpretation by a physician, often needing repeat testing and imaging confirmation
Common tumor markers and their associations (for understanding only, not diagnosis)
Below are 'associations' of common markers and common benign interfering factors (used for monitoring, not diagnosis):
- CEA (carcinoembryonic antigen): associated with colorectal cancer, mainly for monitoring known cancer; also elevated by smoking, inflammatory bowel disease, etc.
- AFP (alpha-fetoprotein): associated with liver cancer and germ cell tumors; often used with ultrasound for high-risk groups; also elevated by pregnancy, hepatitis
- PSA (prostate-specific antigen): associated with the prostate; screening is personalized, shared decision-making with controversy; also elevated by benign prostatic hyperplasia, prostatitis
- CA-125: used for ovarian cancer monitoring, not recommended for general screening; also elevated by menstruation, endometriosis, pregnancy, uterine fibroids
- CA 19-9: associated with pancreatic and biliary tract cancer (mainly monitoring); elevated by benign biliary disease, and about 5–10% of people are non-secretors, so levels may be low even with cancer
- CA 15-3: used for breast cancer monitoring, not for screening
Is it worth including a panel of tumor markers in a self-paid health checkup?
Evidence shows that performing multiple tumor marker panels on asymptomatic healthy individuals has not been proven to reduce mortality, and due to low prevalence, the false positive rate is high, often causing anxiety and unnecessary follow-up tests (e.g., PET, endoscopy). No professional medical organization recommends tumor marker panels for general screening:
- False positives can lead to anxiety, additional invasive follow-up, and costs
- The truly evidence-based screenings that reduce mortality are the government's five-cancer screenings (see below), not tumor marker blood tests
- Whether to add tests should be based on individual risk and discussion with a physician, not on the idea that more panels mean more reassurance
What to do if tumor marker levels are elevated?
First, do not panic. An elevated value does not equal cancer. It needs to be interpreted by a physician in conjunction with your medical history, symptoms, and other tests:
- Discuss with your physician; they may arrange a repeat test or imaging (ultrasound, CT, endoscopy, etc.) for further clarification
- Provide a complete medical history (medications, smoking, chronic diseases, pregnancy, etc., which may affect values)
- Follow up as advised by your physician; this page is neutral information, not personal medical diagnosis or advice
FAQ
If my health check report shows elevated tumor markers, does that mean I have cancer?
Not necessarily. According to the U.S. National Cancer Institute (NCI), elevated tumor markers do not mean cancer—benign causes such as inflammation, infection, smoking, pregnancy, liver/kidney issues can also raise levels; a normal value cannot completely rule out cancer. An isolated abnormal value requires interpretation by a physician in conjunction with medical history and other tests, often necessitating repeat testing or imaging. Please discuss with your doctor; do not panic or self-diagnose.
Can tumor markers be used to screen for cancer?
Most tumor markers are not recommended as standalone screening tools for asymptomatic individuals due to insufficient sensitivity and specificity and high false-positive rates. They are primarily used for treatment monitoring and recurrence tracking in diagnosed patients. A few high-risk groups may have a monitoring role (e.g., liver cirrhosis patients using AFP plus ultrasound for liver cancer surveillance). Diagnosis still requires imaging and pathology.
What are CEA, AFP, PSA, CA-125?
These are common tumor markers: CEA is associated with colorectal cancer, AFP with liver cancer, PSA with the prostate, and CA-125 is used for ovarian cancer monitoring. They are "correlation" indicators used for monitoring, not diagnosis, and can all be elevated due to benign conditions (e.g., smoking, hepatitis, benign prostatic hyperplasia, menstruation). Values must be interpreted by a physician in a clinical context.
Should PSA be tested?
PSA (prostate-specific antigen) screening is a personalized, shared decision-making process, and there is international controversy (e.g., the U.S. USPSTF recommends that men aged 55–69 discuss with their physician before deciding). Benign prostatic hyperplasia and prostatitis can also elevate PSA. It is recommended to discuss individual risks and benefits with a physician before deciding, rather than universal testing.
Is it worth adding a panel of tumor markers to a self-paid health checkup?
Evidence shows that multiple tumor marker panels for asymptomatic healthy individuals have not been proven to reduce mortality, and they have high false-positive rates, causing anxiety and unnecessary follow-up tests. The only evidence-based screening is the government's five-cancer screening. Whether to add tumor markers should be based on individual risk and discussion with a physician, not on the principle that more tests mean more reassurance.
What are the truly effective cancer screenings?
The National Health Administration provides five evidence-based cancer screenings that reduce mortality: Pap smear, mammography, fecal occult blood test (colorectal cancer), oral mucosal examination, and low-dose computed tomography (LDCT) for lung cancer (for heavy smokers or high-risk individuals). These differ from blood tumor marker tests. It is recommended to utilize these resources first; see the 'Government-Subsidized Cancer Screening' section on this site for details.
This page is a neutral compilation of information for reference only, not Medical advice, and does not constitute any diagnostic commitment.